Clinical Trial Update: Tetrodotoxin Open-label Efficacy and Safety Continuation Study [Phase 3]

View source ↗

Summary

Phase 3 open-label continuation study of tetrodotoxin completed, reporting efficacy and safety data for cancer-related pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Tetrodotoxin (tetrodotoxin)

Snippet

Sponsor: Wex Pharmaceuticals Inc. | Conditions: Pain, Cancer | Phase 3 | Status: COMPLETED